Smart patch may replace finger sticks for hospital insulin dosing

NCT ID NCT07194642

Not yet recruiting Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether a continuous glucose monitor (CGM) can safely guide insulin therapy in cancer and transplant patients who are not in the ICU but need IV insulin due to steroids and nutrition. About 80 participants will be randomly assigned to CGM-guided care or standard hourly finger-stick checks. The goal is to see if CGM improves glucose control, reduces low blood sugar, and is preferred by nurses and patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexcom G7 continuous glucose monitor
What this could lead to: If successful, this could make insulin dosing safer and more convenient for hospitalized patients with diabetes who are not in the ICU.
What could go wrong: This is a small pilot study, so results may not apply broadly. The device measures glucose in interstitial fluid, which can lag behind blood glucose, potentially affecting accuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus post-surgical hypoinsulinemia type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.